Li-Fraumeni Syndrome Disease Model: A Platform to Develop Precision Cancer Therapy Targeting Oncogenic p53

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Li-Fraumeni syndrome (LFS) is an autosomal dominant disorder characterized by a high lifetime risk of developing multiple cancers.
• Germline mutations in the TP53 gene, encoding the tumor suppressor protein p53, are the primary cause of LFS.
• TP53 mutations are also prevalent in sporadic human cancers, highlighting the critical role of p53 in tumorigenesis.

Purpose of the Study:

• To review the biology of LFS and the oncogenic functions of mutant p53.
• To evaluate current LFS disease models and therapeutic strategies targeting mutant p53.
• To explore the potential of integrating novel methodologies with LFS induced pluripotent stem cell (iPSC) platforms for precision cancer therapy.

Main Methods:

• Literature review of LFS biology, TP53 mutations, and cancer development.
• Analysis of existing LFS disease models and their limitations.
• Survey of compounds targeting oncogenic p53 and ongoing clinical trials.
• Discussion of integrating advanced techniques, such as iPSC technology, for therapeutic development.

Main Results:

• Mutant p53 plays a significant oncogenic role in cancer development, making LFS a valuable model for studying these malignancies.
• Current LFS models have strengths and limitations in recapitulating the disease and testing therapies.
• Various compounds targeting oncogenic p53 are under investigation, with some progressing through in vitro trials.

Conclusions:

• Li-Fraumeni syndrome serves as a crucial genetic model for understanding p53-associated cancers.
• Targeting mutant p53 represents a promising therapeutic avenue for LFS and other cancers.
• Integrating iPSC technology with LFS models holds potential for developing personalized precision cancer therapies.